Search
NLX-P101
go.drugbank.com/drugs/DB05924ExperimentalNLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease.
AG0301-COVID19
go.drugbank.com/drugs/DB15856InvestigationalAG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University.
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalHuman secretin is a gastrointestinal peptide hormone that regulates secretions in the stomach, pancreas, and liver. The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH l...
Copper
go.drugbank.com/drugs/DB09130ApprovedInvestigationalCopper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptiv...
Tyramine
go.drugbank.com/drugs/DB08841InvestigationalNutraceuticalTyramine acts by inducing the release of catecholamine.
Coccidioides immitis spherule
go.drugbank.com/drugs/DB11294ApprovedCoccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Nitrazepam
go.drugbank.com/drugs/DB01595ApprovedA benzodiazepine derivative used as an anticonvulsant and hypnotic.
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnFirst-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.